A meropenem pharmacokinetics model in patients with haematological malignancies.,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A meropenem pharmacokinetics model in patients with haematological malignancies.
Journal of Antimicrobial Chemotherapy ( IF 5.2 ) Pub Date : 2020-07-31 , DOI: 10.1093/jac/dkaa275
A Contejean _{1,

2} , L Jaffrelot ₃ , S Benaboud _{3,

4} , J-M Tréluyer _{3,

4,

5} , E Grignano _{1,

4} , L Willems ₁ , R Gauzit ₂ , D Bouscary _{1,

4} , I Gana _{3,

4} , S Boujaafar _{3,

4} , S Kernéis _{2,

4} , D Hirt _{3,

4,

6}

Affiliation

Optimal dosing of antibiotics is critical in immunocompromised patients suspected to have an infection. Data on pharmacokinetics (PK) of meropenem in patients with haematological malignancies are scarce.

中文翻译：